Voyager Therapeutics, Inc. (VYGR)
Automate Your Wheel Strategy on VYGR
With Tiblio's Option Bot, you can configure your own wheel strategy including VYGR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VYGR
- Rev/Share 0.7258
- Book/Share 4.1582
- PB 1.1583
- Debt/Equity 0.1648
- CurrentRatio 5.4281
- ROIC -0.4315
- MktCap 267165504.0
- FreeCF/Share -1.9744
- PFCF -2.3066
- PE -2.618
- Debt/Assets 0.1248
- DivYield 0
- ROE -0.3765
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
Initiation | VYGR | Cantor Fitzgerald | -- | Overweight | -- | -- | Jan. 10, 2025 |
Initiation | VYGR | Leerink Partners | -- | Outperform | -- | $15 | Oct. 16, 2024 |
News
Voyager Therapeutics (VYGR) Soars 11.6%: Is Further Upside Left in the Stock?
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.20 per share a year ago.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
Published: March 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ:VYGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
Published: March 17, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ: VYGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
Published: March 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ:VYGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
Published: March 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ:VYGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
Published: March 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ:VYGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
Published: March 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ: VYGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
An Investigation Has Been Launched Into Voyager Therapeutics, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ:VYGR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
Voyager Therapeutics, Inc. Being Investigated on Behalf of Voyager Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed …
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ: VYGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
An Investigation Has Been Launched Into Voyager Therapeutics, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Published: February 25, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ:VYGR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
LEXINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company will participate in multiple upcoming investor conferences: TD Cowen 45th Annual Health Care Conference, in Boston, including a fireside chat at 1:50 p.m.
Read More
An Investigation Has Commenced on Behalf of Voyager Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your VYGR Losses.
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed …
Read More
VOYAGER ALERT: Bragar Eagel & Squire, P.C. is Investigating Voyager Therapeutics, Inc. on Behalf of Voyager Stockholders and Encourages Investors to Contact the Firm
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASDAQ:VYGR) on behalf of Voyager stockholders. Our investigation concerns whether Voyager has violated the federal securities laws and/or engaged in other unlawful business practices.
Read More
Levi & Korsinsky Reminds Voyager Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - VYGR
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed …
Read More
An Investigation Has Been Launched Into Voyager Therapeutics, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ:VYGR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ:VYGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Lost Money on Voyager Therapeutics, Inc. (VYGR)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed …
Read More
The Schall Law Firm Invites Shareholders With Losses In Voyager Therapeutics, Inc. To Join A Securities Fraud Investigation
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ:VYGR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
Investors who Lost Money on Voyager Therapeutics, Inc. Should Contact Levi & Korsinsky about an Ongoing Investigation - VYGR
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed …
Read More
Voyager Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Voyager Therapeutics, Inc. (VYGR)
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed …
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ:VYGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Voyager Therapeutics, Inc. Being Investigated on Behalf of Voyager Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details
Published: February 18, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed …
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
Published: February 18, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ: VYGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Lost Money on Voyager Therapeutics, Inc.(VYGR)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed …
Read More
Voyager Provides Update on SOD1 ALS Gene Therapy Program
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs extends cash runway into mid-2027 – - All other programs remain on track; IND filings expected in 2025 for GBA1 and FA programs - LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).
Read More
About Voyager Therapeutics, Inc. (VYGR)
- IPO Date 2015-11-11
- Website https://www.voyagertherapeutics.com
- Industry Biotechnology
- CEO Alfred W. Sandrock Jr.,
- Employees 172